Jonathan Northrup

Jonathan Northrup has a diverse work experience in the biotechnology and pharmaceutical industries.

Jonathan is currently serving as a Board Member and Advisor for Vasculonics since September 2020. Prior to this, they were the CEO, CoFounder, and Board Member for Stingray Therapeutics starting in June 2018. Additionally, they were a Board Member for Iterion Therapeutics from June 2018.

Before their roles at Stingray and Iterion Therapeutics, Northrup was a Board Member and CoFounder for Salarius Pharmaceuticals since January 2012.

Jonathan also has experience as the CEO, Board Member, and CoFounder of Beta Cat Pharmaceuticals, where they focused on developing small molecules targeting the beta catenin protein in cancer treatment. This role lasted from March 2011 until June 2018.

Northrup's earlier experience includes serving as the COO for Jubilant Innovation, where they led the venturing group for Jubilant Life Sciences. Jonathan was responsible for translational drug development activities from January 2007 until March 2011.

Prior to their time at Jubilant Innovation, Northrup founded and served as the CEO of Horizon Biotechnologies from 2004 to 2006.

Their career began at Eli Lilly, where they held the position of VP, Business Development & Strategy from 1996 to 2004.

Jonathan Northrup completed their Bachelor of Arts (B.A.) degree in Economics from Northwestern University, where they attended from 1970 to 1974. Following this, they pursued a Master of Business Administration (MBA) degree with a focus on Finance, Accounting, and Marketing from The Wharton School. Jonathan successfully completed their MBA from 1974 to 1976.